spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

7th annual Orphan Drugs and Rare Diseases UK

SMI - Orphan Drugs and Rare Diseases UK

18-19 October 2017
Holiday Inn Kensington Forum, London

Orphan Drugs and Rare Diseases UK 2017: Discussing strategies for patient engagement, market access and gene therapies to enhance rare disease and orphan drug research.

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.

Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.

Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.

Chairs for 2017:

• Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
• Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
Expert Speaker Line-Up Includes:

• Oliver Timmis, CEO, AKU Society
• Stuart Hughes, Director, Head of Pharmacology, Vertex
• Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
• Christine Lavery, Group Chief Executive, MPS Society
• Hsin Loke, Director, Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
• Olaf Ritzeler, External Innovation Lead, Sanofi
• Stephen Marcus, CEO, Cantex Pharmaceuticals
• Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences

Exclusive highlights in 2017:

• Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
• Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
• Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more
• Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug repurposing in the rare disease area can help treatment
Other event highlights include an exclusive pre-conference interactive workshop carefully selected to enhance your conference experience and encourage personal and professional development. Places are strictly limited to ensure optimal learning for attendees.

Rare Diseases Challenges and Opportunities
Tuesday 17th October 2017 | 13.30 – 17.30
Workshop Leaders: Birmingham Children’s Hospital.
phone Tel: +44 (0) 207 827 6012
email kwilliams@smi-online.co.uk
web www.orphandrugs.co.uk/samedan
email London, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

Partnerships in Clinical Trials Europe 2017

28-29 November 2017, RAI, Amsterdam

PCT Europe is back, bringing you the latest information from across the clinical trials spectrum and providing you with direct access to the industry's leading innovators. And this year, we're in Amsterdam!
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>


News and Press Releases

New research confirms correlation of common bacteria (including MRSA) and eczema


More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement